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Objective: To quantitatively determine the prevalence
of anxiety and depression in men on active surveillance
(AS).
Design: Cross-sectional questionnaire survey.
Setting: Secondary care prostate cancer (PCa) clinics
across South, Central and Western England.
Participants: 313 men from a total sample of 426 with
a histological diagnosis of PCa currently managed with
AS were identified from seven UK urology departments.
The mean age of respondents was 70 (51–86) years
with the majority (76%) being married or in civil
partnerships. 94% of responders were of white British
ethnicity.
Primary outcome measures: The prevalence of
clinically meaningful depression and anxiety as
assessed by the Hospital Anxiety and Depression Scale
(HADS; score ≥8/21).
Secondary outcome measures: Patient
demographic data (age, employment, relationship,
ethnic and educational status). Each demographic
variable was cross-tabulated against patients identified
as depressed or anxious to allow for the identification of
variables that were significantly associated with
depression and anxiety. In order to determine predictors
for depression and anxiety among the demographic
variables, logistic regression analyses were conducted,
with p<0.05 considered as indicating statistical
significance.
Results: The prevalence of clinical anxiety and
depression as determined via the HADS (HADS ≥8) was
23% (n=73) and 12.5% (n=39), respectively. Published
data from men in the general population of similar age
has shown prevalence rates of 8% and 6%, respectively,
indicating a twofold increase in depression and a
threefold increase in anxiety among AS patients. Our
findings also suggest that AS patients experience
substantially greater levels of anxiety than patients with
PCa treated radically. The only demographic predictor
for anxiety or depression was divorce.
Conclusions: Patients with PCa managed with AS
experienced substantially higher rates of anxiety and
depression than that expected in the general population.
Strategies to address this are needed to improve the
management of this population and their quality of life.
INTRODUCTION
Prostate cancer (PCa) represents the most
common form of non-cutaneous malignancy
diagnosed in British men.1 The number of
men being diagnosed with PCa continues to
rise annually as a result of increased PSA
testing and an ageing population.2 Men with
a diagnosis of low-risk PCa face a decision
between radical treatments such as surgery
and brachytherapy, and active surveillance
(AS).
AS aims to personalise the management of
PCa by ensuring that only those men with
clinically relevant disease are selected for
curative treatment. Analysis of several large
case series suggests that around four in ﬁve
men will remain untreated at 2 years, with a
recent UK series reporting adverse histology
of 22% at a median of 5.7 years, with
treatment-free probability of 70% at that
time point.3
There is doubt about the utility of radical
surgery for men with low-risk disease as it has
been shown to have no signiﬁcant beneﬁt on
12-year survival.4 Radical surgery is also asso-
ciated with signiﬁcantly greater risk of long-
term incontinence (17.1%) and impotence
(81.1%) than AS.4 The recently updated
(2014) UK National Institute for Health and
Strengths and limitations of this study
▪ This is the largest multicentre assessment of
depression and anxiety prevalence in active sur-
veillance patients yet to be undertaken.
▪ Our cross-sectional methodology makes it diffi-
cult to draw definitive conclusions about the
causality of anxiety and depression in this popu-
lation, and how these conditions vary over time.
▪ Our anonymous recruitment policy means that
we are unable to account for nor determine dif-
ferences between responders and non-
responders.
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Care Excellence (NICE) guidelines currently recom-
mend AS as the preferred management option for men
with low-risk localised PCa.5
While the maintenance of physical and sexual function
is a major advantage of AS, little is currently known about
the psychological consequences of this strategy. Much
research has highlighted the psychological beneﬁts of
early active treatment initiation among patients with
cancer.6 7 Beneﬁts include feelings of empowerment,
hope and reassurance.6–8 It has been proposed that men
who choose AS may be at greater risk of psychological dis-
tress because of the passive nature of the strategy.9
Burnet et al10 assessed psychological distress in 100 men
on AS in a single-centre UK study. They reported a high
prevalence of anxiety and a low prevalence of depression
(21% and 4%, respectively). Van den Bergh et al11 12
assessed depression and anxiety in 129 men on AS from
the Prostate Cancer Research International (PRIAS) study,
and also reported a low prevalence of depression (8%)
and a high prevalence of anxiety (17%).
These ﬁndings suggest that the prevalence of anxiety
in this patient population may be two to three times
greater than that found in men of similar age in the
general population.13 Crucially, anxiety is known to be a
signiﬁcant predictor in identifying which men on AS will
transfer to radical treatment in the absence of a change
in histology or PSA.14 15 The assessment and manage-
ment of anxiety in this patient population should, there-
fore, be viewed as an area of key clinical importance to
help prevent this transference and the debilitating phys-
ical side effects that accompany it.
The primary aim of the current investigation was to
address this issue by undertaking a large cross-sectional
assessment of the prevalence of clinical anxiety and
depression in a large cohort of AS patients from mul-
tiple centres across the UK. It was hoped that by doing
so we would provide a geographically diverse, ethnically
varied, clinically relevant and more deﬁnitive estimate of
the psychological health of this patient group. A second-
ary aim was to determine whether any demographic vari-
ables were able to predict which AS patients were most
likely to experience depression and anxiety.
METHODS
The coordinating site for the running of this study was
Southampton University Hospitals Trust. Six additional
National Health Service (NHS) Trust sites (Great
Western, Mid-Essex, Coventry and Warwickshire, Weston
Area Foundation, University College London Hospitals,
and Surrey and Sussex NHS Trust Foundations) were
recruited as secondary sites. Sponsorship was obtained
by Southampton University Hospitals Trust.
Participants were recruited consecutively over a
7-month period from May 2012 to December 2012. To
be eligible for entry into the study, each participant had
to meet all of the following criteria which were standar-
dised across all seven recruitment centres:
▸ A biopsy-conﬁrmed diagnosis of PCa.
▸ Diagnosis received at least 2 months prior to entry
into the study to minimise acute, postdiagnosis mood
disturbances.
▸ Currently being managed with AS.
▸ Be ﬂuent in the English language (questionnaires
were written and validated in English).
▸ Have no additional cancer diagnoses.
▸ Have no other serious or life-threatening comorbidity
that could signiﬁcantly impact on mood such as
late-stage cardiovascular disease, kidney failure or
stroke.
To help maximise recruitment, all patients meeting
the inclusion criteria were eligible for entry into the
study. No restrictions or parameters were put in place in
terms of patient age or time since diagnosis. Records at
each of the seven centres were screened to identify
patients who met the above inclusion criteria. All eligible
patients were then sent by post a Patient Information
Pack (PIP). The PIP included a Patient Invitation Letter,
a Hospital Anxiety and Depression Scale (HADS16), a
Patient Demographic Questionnaire (PDQ) and a free-
post return envelope. Participants wishing to take part in
the investigation were asked to anonymously complete
and return both of the enclosed questionnaires. An
anonymous recruitment policy was adopted based on
the advice of Berkshire Research Ethics Committee.
While doing so safeguarded patient identity and security,
it did mean that we were unable to identify responders
and non-responders, nor screen their records to collect
relevant clinical data on issues such as date of diagnosis
and a history of psychological morbidity.
The HADS is a well-validated and reliable question-
naire that has been used extensively within the ﬁeld of
oncology to assess depression and anxiety.17–20 Seven
questions relate to symptoms of depression and seven to
anxiety. The maximum score is 21 for both the anxiety
and depression subscales. In the current investigation,
depression and anxiety were deemed to exist in patients
with a HADS score of ≥8, based on the recommenda-
tions of Zigmond and Snaith.16 The PDQ was developed
by the research team at the University of Southampton
to measure the key demographic information required
for this study (age, ethnic, employment, relationship
and educational status).
Data from the returned questionnaires were trans-
ferred to SPSS V.19.0 for analysis. Descriptive statistics
were computed to estimate the percentage prevalence of
depression and anxiety (% of participants scoring ≥8 on
each of the HADS subscales). Each of the collected
demographic variables were cross-tabulated against
patients identiﬁed as depressed or anxious to allow for
the identiﬁcation of any variables that were signiﬁcantly
associated with depression and anxiety. Finally, in order
to determine predictors for depression and anxiety
among the demographic variables, logistic regression
analyses were conducted, with p<0.05 considered as indi-
cating statistical signiﬁcance.
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RESULTS
Three hundred and thirteen participants out of an
approached sample of 426 (73.47%) were recruited
from seven NHS Trust sites into the current investigation
(table 1). A sample of this size provided sufﬁcient preci-
sion to estimate the percentage of men who were
depressed and anxious using a 95% CI within 4% of the
true value. The mean age of the patients was 70.49 years
(range 51–86). Most participants were retired (74.44%)
and married/in civil partnership (76.99%); 36.6% had
completed their education to secondary school level,
while 32.3% completed college/specialised training.
The majority of participants (93.8%) were of white
British ethnicity. Eight men did not disclose their age,
and ﬁve did not complete the remainder of the demo-
graphic questions.
Across the 313 participants, the mean depression
score was 3.269 (SD=3.569), with scores ranging from 0
to 18. Thirty-nine participants (12.5%) obtained a score
of ≥8 on the HADS-D, indicating the existence of clin-
ical depression. The mean anxiety score across the 313
participants was 4.84 (SD=3.791), with scores ranging
from 0 to 20. Seventy-three participants (23.3%)
recorded a score of ≥8 on the HADS-A, indicating clin-
ical anxiety (table 2).
Only one cross-tabulation of demographic variables
against depressed or anxious cases showed a signiﬁcant
variation in the prevalence of either condition around
the overall estimates (relationship status vs anxiety).
Although very few divorced men were included in the
study, this ﬁnding suggests that divorced patients have a
higher prevalence of anxiety (56%) compared with the
overall rate of 23.1% (table 3).
PREDICTORS OF DEPRESSION AND ANXIETY
Depression
Each demographic variable was used as a possible pre-
dictor to determine whether it could be included in the
logistic regression model to improve its predictive value.
A stepwise analysis was utilised for this purpose where
the p value for entry was taken by default as 0.05. The
results indicated that ‘Southampton’ was the best single
predictor with a p value <0.0005. None of the other
Table 1 Patient demographic characteristics























Range 55–86 53–72 62–72 50–79 71–81 51–77 50–81 51–86
Employment status
Full-time employment 4 10 0 16 0 7 4 41
Part-time employment 4 5 4 3 0 6 6 28
Retired 19 72 7 69 15 10 42 234
Unemployed 1 1 0 3 0 0 0 5
Unknown 0 1 3 1 0 0 0 5
Relationship status
Co-habiting 2 5 0 1 0 2 4 14
Divorced 4 0 1 5 2 2 2 16
Married/civil partnership 18 70 10 75 9 17 40 239
Single 0 2 0 7 0 2 5 16
Widowed 4 11 0 3 4 0 1 23
Unknown 0 1 3 1 0 0 0 5
Education status
Left school before age 15 3 23 0 18 4 0 8 56
Completed secondary education 18 27 6 27 6 5 17 106
College/specialised training 6 31 3 34 4 5 16 99
University 2 7 2 12 1 13 10 47
Unknown 0 1 3 1 0 0 0 5
Ethnicity
White British 28 85 11 87 15 19 51 296
White Other 0 1 0 3 0 2 0 6
Afro-Caribbean 0 2 0 0 0 2 0 4
Asian 0 0 0 2 0 0 1 3
Other 0 1 0 0 0 0 0 1
Unknown 0 0 3 0 0 0 0 3
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variables were signiﬁcant with the next lowest p value
being 0.119 for ‘Single’ (table 4).
Table 5 shows the estimated model parameters at step
1 of the logistic regression with only Southampton
included, and also those for the logistic regression with
Southampton already in the model and the variable
Single entered as the next most signiﬁcant predictor,
with a p value of 0.055.
The OR for Southampton was 4.904 and 5.422 for
both steps 1 and 2, indicating that there is a higher
chance of being depressed among the men from
Southampton. When these variables were included in
the logistic regression model in turn and the probability
of being a depressed man was evaluated for each patient
(table 6) none of the probabilities were increased sufﬁ-
ciently to change the proportion of correctly classiﬁed
men. The cut-off value for the estimated probability of
being depressed was taken to be 0.5.
Anxiety
The logistic regression analysis performed for depression
was repeated to investigate predictions of anxiety using the
demographic variables. Each variable used as a possible
predictor was assessed to see whether it could be included
in the model to improve its predictive value (table 7).
Divorce was the only signiﬁcant variable and was
added into the model. The logistic regression parameter
estimates for predicting anxiety using divorced were
shown to be insigniﬁcant (table 8).
DISCUSSION
We observed a high prevalence of depression and anxiety
in men with PCa being managed with AS, but were
unable to identify any clear demographic predictors for
these conditions other than being divorced. Based on the
most recent UK statistics, the prevalence of depression
and anxiety in British men aged over 65 is 6% and 8%,
respectively.13 Our results from the HADS suggest that AS
patients may be more than twice as likely to be depressed
and three times as likely to be anxious, compared with
men of similar age in the community. Across the 313
recruited AS patients, the mean scores of depression and
anxiety were low at 3.27 (SD 3.33) and 4.84 (SD 3.85),
respectively. However, using the standardised threshold
of ≥8 on the HADS to deﬁne caseness, 12.5% (n=39) of
participants met the criteria for clinically meaningful
depression and 23.3% (n=73) for anxiety.
AS patients who were divorced had a signiﬁcantly
higher prevalence of anxiety. None of the additional
demographic variables had any signiﬁcant power to
predict which men were most likely to be experiencing
depression or anxiety. Such ﬁndings suggest that the
men deﬁned as depressed and anxious in this study
were a demographically heterogeneous group. Other
smaller studies have identiﬁed that variables such as
impaired mental health and the patient’s perceived
importance of the physician in the treatment decision-
making process appear to be associated with poorer
quality of life among AS patients.11 21 This would
suggest that variables other than the simple data set col-
lected in our current study may be able to predict which
AS patients are most vulnerable to psychological distress.
Further research is needed to help clarify this situation.
Several important limitations exist within the current
study. We did not recruit a cohort of patients with PCa
who were receiving radical treatment. We are, therefore,
unable to determine how the prevalence rates of
HADS-based depression and anxiety observed in the AS
patients compare to those seen in patients receiving
radical treatment. The only previous study that has
attempted to answer this question reported that AS
patients experienced over twice the prevalence of
anxiety and an equal prevalence of depression as radic-
ally treated patients.10
Likewise, while our ﬁndings suggest that AS patients
experience a much greater prevalence of anxiety and
depression when compared with men of a similar age
without PCa,13 our conclusions are drawn from indirect
comparisons with previously conducted research rather
Table 2 Mean Hospital Anxiety and Depression Scale (HADS) scores and prevalence data
Mean (with 95% CIs) SE Median SD Minimum Maximum Caseness (HADS ≥8)
HADS—D (depression) 3.269 (2.9 to 4.3) 0.281 2 3.569 0 18 N=39 (12.46%)
HADS—A (anxiety) 4.84 (4.4 to 5.3) 0.299 4 3.791 0 20 N=73 (23.32)
Table 3 Anxious versus relationship cross-tabulation
Co-habiting Divorced Married Single Widowed Total
Non-anxious (n) 10 7 187 12 21 237
Within relationship (%) 71.4 43.8 78.2 75 91.3 76.9
Anxious (n) 4 9 52 4 2 71
Within relationship (%) 28.6 56.3 21.8 25 8.7 23.1
Total 14 16 239 16 23 308
χ2=13.114, p=0.011.
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than from direct comparisons with an age-matched
control group. Furthermore, directly comparing clinical
populations with population-based controls is not always
a legitimate form of comparison for a variety of reasons,
including biases such as Berkson’s bias. To address this
is would be helpful for future research to assess how the
prevalence of depression and anxiety among AS patients
varies in comparison to populations of patients with PCa
treated radically.
Similarly, the depression and anxiety prevalence data
generated in this study were collected by the HADS.
However, as the HADS excludes any somatic symptoms
of depression and anxiety, our deﬁnition of these condi-
tions are not consistent with the common clinical
deﬁnitions of generalised anxiety disorder and major
depressive disorders, which all include somatic symp-
toms. There, therefore, exists an important discrepancy
between our deﬁnition of depression and anxiety in this
patient cohort, and that based on a clinical diagnosis
that utilises somatic symptomology.
As a cross-sectional survey, we were also unable to assess
how the prevalence of depression and anxiety may have
altered over time. Anxiety tends to peak among AS patients
3–4 weeks prior to PSA testing and subsides substantially, if
the subsequent clinical outcome indicates a lack of disease
progression.22 The cross-sectional nature of the current
investigation, coupled with the required anonymised
recruitment process, made it impossible to determine
where each patient was with regard to both their PSA mon-
itoring schedule and how long ago were they diagnosed.
Both of these issues may possibly have had some impact on
the survey outcome, particularly as time from diagnosis has
been shown to be a signiﬁcant predictor of maladaptive
adjustment to PCa.21 However, as a cross-sectional survey,
this investigation was not designed to determine causality
or longitudinal changes in psychological morbidity, but
did additional longitudinal investigations that assess
depression and anxiety at the time of diagnosis up to the
selection of AS, and therefore, the subsequent long-term
follow-up are vital to help us address this issue.
The anonymous recruitment process that we adopted
at the request of our local Research Ethics Committee
meant that we were unable to account for a history of
depression and anxiety. Depressed and anxious patients
with cancer are less likely to complete and return ques-
tionnaires than their non-depressed and non-anxious
counterparts.23 It is, therefore, possible that the preva-
lence data generated represent an underestimate of dis-
tress. This limits the generalisabilty of our ﬁndings.
Similarly, the anonymous recruitment process meant
that we were unable to compare how responders dif-
fered from non-responders both clinically and demo-
graphically. It also meant that we were unable to initiate
a second round of recruitment in a bid to recruit a sub-
group of responders from the overall pool of non-
responders. While this limits the generalisability of our
ﬁndings, it was a decision driven by the requirements of
our governing Research Ethics Committee.
Lastly, our ﬁnding that divorced patients experienced
a higher prevalence of anxiety was interesting. However,
Table 4 Significant predictors of depression
Included levels Score df Significance
Full time 0.003 1 0.956
Part time 0.821 1 0.365
Retired 1.547 1 0.214
Semiretired 0.143 1 0.706
Unemployed 0.584 1 0.445
Co-habiting 0.045 1 0.832
Divorced 0 1 0.996
Married 0.514 1 0.473
Single 2.431 1 0.119
Widowed 1.498 1 0.221
Asian 0.287 1 0.594
BA 0.143 1 0.706
BC 0.431 1 0.511
Chinese 0.143 1 0.706
WB 0.443 1 0.505
WO 0.099 1 0.753
College 0.265 1 0.607
Specialist college 0.596 1 0.44
Left school <15 0.129 1 0.719
Secondary 0.215 1 0.643
University 0.701 1 0.403
Coventry 1.693 1 0.193
Essex 1.081 1 0.299
London 0.323 1 0.57
SASH 1.3 1 0.254
Southampton 15.245 1 0
Swindon 0.119 1 0.73
Western-S-M 2.243 1 0.134
df, degrees of freedom.
Table 5 Logisitic regression for depression with 95% CIs
B SE Wald df Significance OR 95% CIs
Step 1
Southampton 1.590 0.440 13.037 1 0.000 4.904 2.07 to 11.62
Constant −2.178 0.196 123.555 1 0.000 0.113
Step 2
Single 1.180 0.614 3.687 1 0.055 3.253 0.97 to 10.84
Southampton 1.691 0.447 14.314 1 0.000 5.422 2.26 to 13.02
Constant −2.278 0.210 117.705 1 0.000 0.102
df, degrees of freedom.
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it is important to note that the observed association
between anxiety and divorce may more accurately reﬂect
association with the incidence of PCa.
Important strengths of the current study include its
multicentre recruitment, large sample size and high
response rate which are very likely to have minimised the
effect of any of the above potential confounders.
Previous investigations into the prevalence of psycho-
logical distress in AS patients have involved small patient
samples10–12 which substantially limits the representative-
ness and generalisability of their ﬁndings. Our results,
therefore, provide a more robust and conﬁdent assess-
ment of psychological distress. Furthermore, previous
investigations of AS patients have typically recruited
patients from single sites which further limits their gener-
alisabilty. In the current investigation, men were recruited
from seven independent NHS Trust locations across
South, Western and Central England and thus, increased
both patient diversity and generalisabilty as well as allow-
ing us to investigate some demographic predictors.
Nevertheless, over 95% of participants were of white
British origin representing an extremely homogeneous
ethnic sample. This means we have very little under-
standing of how men from other ethnic communities
may respond and cope with a PCa diagnosis and subse-
quent management with AS.
The work by Burnet et al10 compared men who were
either currently receiving radical treatment with radio-
therapy+neoadjuvant hormone therapy, or who had pre-
viously received radical radiotherapy with those on AS.
Burnet et al10 suggest a lack of signiﬁcant difference in
psychological morbidity between patients with PCa
treated radically and those being managed with AS.
However, those being managed with AS had over twice
the prevalence of anxiety as those who were currently
receiving treatment (21% vs 10%), with 15% of men
who had completed treatment exceeding the threshold
for clinically relevant anxiety. The patient numbers
involved meant this factor did not emerge as a statistic-
ally signiﬁcant observation.
Our ﬁndings appear to be consistent with those gener-
ated from smaller investigations into psychological dis-
tress among AS patients.10–12 These investigations have
all shown a lower prevalence of depression (<10%) and
a higher prevalence of anxiety (17–21%). This was a
pattern very clearly mirrored in the current study. In
light of our large multicentre sample size, our ﬁndings
would appear to support the initial conclusions from
these previous, smaller investigations.
Similarly, our ﬁndings provide a unique insight into
how the prevalence of psychological distress in AS
patients compares to that observed among patients with
PCa treated radically. Recently published meta-analysis
data collected from a pooled sample of over 4000 patients
with PCa have revealed a depression and anxiety preva-
lence of 14.70% (95% CI 11.92% to 17.99%) and 15.09%
(95% CI 12.15% to 18.60%), respectively, among patients
with PCa undergoing radical treatment.24 The ﬁndings of
the current study, therefore, suggest that men managed
with AS experience a slightly lower prevalence of depres-
sion and a substantially higher prevalence of anxiety than
men treated radically. This is an important ﬁnding as it is
the ﬁrst large multicentre study to highlight the potential
anxiety inducing nature of AS when used as a manage-
ment approach for localised PCa.
In conclusion, we have identiﬁed the presence of con-
siderable distress in this population, and the consequent
need for the development and implementation of fra-
meworks that will allow for the better management of
anxiety in men receiving AS. To be effective, it is likely
that such interventions will need to target and address
AS patient’s health literacy to allow them to better
Table 6 Classification of depressed men with the
















Table 7 Significant predictors of anxiety
Full time 0.993 1 0.334
Part time 0.048 1 0.826
Retired 2.943 1 0.086
Semiretired 3.298 1 0.069
Unemployed 1.612 1 0.204
Co-habiting 0.226 1 0.635
Divorced 10.223 1 0.001
Married 1.385 1 0.239
Single 0.027 1 0.871
Widowed 2.97 1 0.085
Asian 0.612 1 0.434
BA 3.298 1 0.069
BC 0.921 1 0.337
Chinese 0.305 1 0.581
WB 0.373 1 0.542
WO 0.343 1 0.558
College 0.031 1 0.859
Specialist college 0.158 1 0.691
Left school <15 0.058 1 0.809
Secondary 0.009 1 0.923
University 0.426 1 0.514
Coventry 0.52 1 0.471
Essex 3.127 1 0.077
London 0.702 1 0.402
SASH 1.262 1 0.261
Southampton 1.338 1 0.247
Swindon 0.05 1 0.822
Western-S-M 0.097 1 0.755
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understand, process, rationalise AS and thus, minimise
their anxiety.
Self-care interventions that equip patients with PCa
with psychological, educational and informational
support, either remotely via the internet or in group-
based environments, have shown some initial success in
lowering psychological distress and improving health-
related quality of life.25 To date, self-care interventions
such as these have yet to be trialled speciﬁcally with a
population of AS patients. These may offer an appropri-
ate, clinically effective and economically sustainable
means of support for this patient cohort. Future
research should aim to address this issue to ensure that
psychological distress in this patient group does not go
underdiagnosed and undermanaged.
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